StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Did some calculation

<< Previous

Bullboard Posts

Next >>

Comment by IainCaimbeulon Jan 13, 2022 2:34pm

100 Views

Post# 34313914

RE:RE:RE:RE:RE:RE:RE:RE:Did some calculation

molotov420 wrote: We have all heard how good the product is for years. When it boils down to it, we need to know people will pay for it and SZLS can sell it. With out that unfortunately the product is worthless.

Ten months since Aristotle rollout and crickets from StageZero regarding sales. Comments from Rebecca that we are selling is pretty much useless without numbers.
Other commenters here might as well base their opinons on their astrology sign, it would make as much sense.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Oct. 1, 2024